#SFHS2611620AFrance Adds FUBELV to the Approved Medicines List for Public Healthcare Use
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order adds three FUBELV pharmaceutical products to the list of medicines approved for use by public hospitals, local authorities, and other public services in France. Health insurance coverage is limited to specified indications, including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, juvenile idiopathic arthritis, and plaque psoriasis. Hospitals, prescribers, and reimbursement teams should apply the coverage rules only for the listed patient groups and treatment conditions.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds three FUBELV products to France’s approved medicines list for public healthcare use
- Limits health insurance coverage to specified inflammatory joint and skin conditions
- Defines age groups and prior-treatment conditions for reimbursement in adult, adolescent, and pediatric patients
Obligations
What this law requires
Public hospitals, local authorities, and other public services may include the three listed FUBELV pharmaceutical specialties on the approved list of medicines for collective/public-service use only as specified in the annex.
Health insurance reimbursement for FUBELV must be limited to the therapeutic indications expressly listed in the annex; uses outside those indications do not open a right to coverage under this order.
For rheumatoid arthritis, FUBELV coverage must be applied only for adults with moderately to severely active disease after inadequate response to disease-modifying antirheumatic drugs, including methotrexate, unless methotrexate is contraindicated; monotherapy is covered only where methotrexate is intolerable or inappropriate.
For psoriatic arthritis, FUBELV coverage must be applied only for adults with active and progressive psoriatic arthritis after inadequate response to prior disease-modifying treatment.
For axial spondyloarthritis, FUBELV coverage must be applied only for adults with severe active ankylosing spondylitis after inadequate response to conventional treatment, or severe non-radiographic axial spondyloarthritis with objective inflammation shown by elevated CRP and/or MRI signs after inadequate response to NSAIDs.